Sezione di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Piazza delle Cliniche 2, Palermo, Italy.
Expert Rev Anticancer Ther. 2011 Dec;11(12):1807-16. doi: 10.1586/era.11.139. Epub 2011 Aug 26.
Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessment of liver disease and its complications, and efficacy and safety of this molecule. Particular emphasis is given on how to improve tolerability of sorafenib in difficult-to-treat patients.
索拉非尼（多吉美®，拜耳），一种多靶点酪氨酸激酶抑制剂，是首个在肝功能良好的晚期肝细胞癌患者的总生存期方面显示出显著改善的全身治疗药物。目前该药被推荐用于晚期肝细胞癌患者的一线治疗以及不适宜局部治疗的患者。本文由包括胃肠病学和肿瘤学专家在内的多学科小组撰写，概述了索拉非尼治疗肝细胞癌的主要问题，包括分期和预后策略、肝脏疾病及其并发症的评估，以及该分子的疗效和安全性。特别强调了如何改善难以治疗的患者对索拉非尼的耐受性。
